Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30918006 | 1.00 | ACHE (0.45) | ACHEDRD1HTR6GRIN2B | |
| SCHEMBL2038159 | 1.00 | ACHE (0.45) | ACHEDRD1HTR6GRIN2B | |
| Hydrochloric Acid SCHEMBL8191914 | 0.98 | ACHE (0.48) | ACHEDRD1HTR6GRIN2B | |
| SCHEMBL30400877 | 0.88 | ACHE (0.49) | ACHEDRD1HTR6 | |
| SCHEMBL3533926 | 0.88 | ACHE (0.49) | ACHEDRD1HTR6 | |
| SCHEMBL396737 | 0.88 | ACHE (0.49) | ACHEDRD1HTR6 | |
| Hydrochloric Acid SCHEMBL11744676 | 0.86 | ACHE (0.48) | ACHEDRD1HTR6 | |
| SCHEMBL3439729 | 0.83 | DRD2 (0.39) | ACHEDRD1HTR6GRIN2B | |
| SCHEMBL12548647 | 0.83 | DRD2 (0.39) | ACHEDRD1HTR6GRIN2B | |
| SCHEMBL8223471 | 0.83 | DRD2 (0.39) | ACHEDRD1HTR6GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-RE37438-E1 | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. | 2001-11-06 | — | — | US | disclosed |
| US-5866612-A | Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase | GLAXO WELLCOME INC. (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0799191-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1997006158-A1 | BICYCLIC AMIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-02-20 | — | — | WO | disclosed |
| WO-1996019440-A1 | ACETAMIDINE DERIVATIVES AND THEIR USE AS INHIBITORS FOR THE NITRIC OXIDE SYNTHASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | ACHE 488/4885DRD1 1862/4885HTR6 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.